Clinical Trials in Chicago

Showing 8901-8920 of 20,493 trials

Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)

NCT02345330

This study will assess the safety and effectiveness of ImmunoPulse IL-12® in treatment-refractory metastatic and unresectable squamous cell carcinoma of the head and neck (HNSCC). ImmunPulseIL12® is the combination of intrtumoral interleukin-12 gene (also known as tavokinogene telseplasmid \[tavo\]) and in vivo electroporation-mediated plasmid deoxyribonucleic acid \[DNA\] vaccine therapy (tavo-EP) administered using the OncoSec Medical System (OMS). Intratumoral tavo is a gene therapy approach to directly induce a pro-inflammatory response within a tumor to initiate and/or enhance anti-tumor immunity.

Head and Neck Squamous Cell Carcinoma

OncoSec Medical Incorporated4 participantsStarted May 2015

San Francisco, California, United States • Chicago, Illinois, United States

COMPLETEDPhase 32.2 miles

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

NCT01969838

This study is to determine the efficacy of momelotinib (MMB) versus ruxolitinib (RUX) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) who have not yet received treatment with a Janus kinase inhibitor (JAK inhibitor). Participants will be randomized to receive either MMB or ruxolitinib for 24 weeks during a double-blind treatment phase, after which they will be eligible to receive open-label MMB for up to an additional 216 weeks. After discontinuation of study medication, assessments will continue for 12 additional weeks, after which participants will be contacted for survival follow-up approximately every 6 months for up to 5 years from the date of enrollment or until study termination. For those participants planning to continue treatment with MMB following the end of the study, the Early Study Drug Discontinuation (ESDD), 30-day, 12-Week, and survival follow-up visits are not required.

Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis

Sierra Oncology LLC - a GSK company432 participantsStarted Dec 2013

Phoenix, Arizona, United States • Escondido, California, United States • Stanford, California, United States +111 more locations

Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

Find Trials by Condition in Chicago

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

RISE Adult Medication Study

12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)

TMP-Visitas al Hogar

Newborn Implementation

A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease

A PRospective, rAndomizEd Comparison of subcuTaneOous and tRansvenous ImplANtable Cardioverter Defibrillator Therapy

Keeping it LITE: Exploring HIV Risk in Vulnerable Youth With Limited Interaction and Digital Health Intervention

ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent

rhBMP-2/CRM/CD HORIZON® Spinal System Pivotal Study

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

A Clinical Evaluation of the Treatment of Spider Veins on the Ankles

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

Study of ASN003 in Subjects With Advanced Solid Tumors

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

P3 Long Term Safety Study of Once Daily SB204 in Acne

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy